Evidence map›Paper›PMID 26531195›Full record

ArticleMolecular biology and evolution2016

SHV-129: A Gateway to Global Suppressors in the SHV β-Lactamase Family?

Marisa L Winkler, Robert A Bonomo

Open access · hybridAbstract read
In one paragraph

Article in Molecular biology and evolution, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Marisa L WinklerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH Department of Molecular Biology and Microbiology, Case Western Reserve University.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH Department of Molecular Biology and Microbiology, Case Western Reserve University Department of Pharmacology, Case Western Reserve University Department of Biochemistry, Case Western Reserve University Department of Medicine, Case Western Reserve University robert.bonomo@va.gov.
Case Western Reserve University · USLouis Stokes Cleveland VA Medical Center · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
NIAID NIH HHS AI063517-07NIAID NIH HHS AI072219-05NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32-GM007250
6 · The paper itself

Abstract

Enzymes are continually evolving in response to environmental pressures. In order to increase enzyme fitness, amino acid substitutions can occur leading to a changing function or an increased stability. These evolutionary drivers determine the activity of an enzyme and its success in future generations in response to changing conditions such as environmental stressors or to improve physiological function allowing continual persistence of the enzyme. With recent warning reports on antibiotic resistance and multidrug resistant bacterial infections, understanding the evolution of β-lactamase enzymes, which are a large contributor to antibiotic resistance, is increasingly important. Here, we investigated a variant of the SHV β-lactamase identified from a clinical isolate of Escherichia coli in 2011 (SHV-129, G238S-E240K-R275L-N276D) to identify the first instance of a global suppressor substitution in the SHV β-lactamase family. We have used this enzyme to show that several evolutionary principles are conserved in different class A β-lactamases, such as active site mutations reducing stability and requiring compensating suppressor substitutions in order to ensure evolutionary persistence of a given β-lactamase. However, the pathway taken by a given β-lactamase in order to reach its evolutionary peak under a given set of conditions is likely different. We also provide further evidence for a conserved stabilizing substitution among class A β-lactamases, the back to consensus M182T substitution. In addition to expanding the spectrum of β-lactamase activity to include the hydrolysis of cefepime, the amino acid substitutions found in SHV-129 provide the enzyme with an excess of stability, which expands the evolutionary landscape of this enzyme and may result in further evolution to potentially include resistance to carbapenems or β-lactamase inhibitors.

Indexed as

Multigene FamilySuppression, GeneticAmino Acid SequenceAmino Acid Substitutionbeta-Lactamase Inhibitorsbeta-LactamasesDrug Resistance, BacterialEscherichia coliEvolution, MolecularHumansKineticsMicrobial Sensitivity TestsModels, MolecularMolecular Sequence DataMutationProtein Conformationbeta-Lactamase Inhibitorsbeta-Lactamasesantibiotic resistanceglobal suppressorsprotein evolutionβ-lactamase

Identifiers

PMID26531195
PMCPMC4909130
OpenAlexW2189685018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.